Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald lifted their target price on Biohaven Pharmaceutical from $87.00 to $92.00 and gave the company an overweight rating in a research note on Monday, October 28th. William Blair reissued a buy rating on shares of Biohaven Pharmaceutical in a research note on Tuesday, September 17th. Oppenheimer set a $67.00 target price on Biohaven Pharmaceutical and gave the company a buy rating in a research note on Wednesday, October 9th. Goldman Sachs Group set a $89.00 target price on Biohaven Pharmaceutical and gave the company a buy rating in a research note on Wednesday, September 4th. Finally, Zacks Investment Research cut Biohaven Pharmaceutical from a buy rating to a hold rating in a research note on Monday, October 21st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $71.80.
Shares of NYSE BHVN traded up $2.06 during midday trading on Thursday, hitting $51.08. The stock had a trading volume of 881,221 shares, compared to its average volume of 487,177. The company’s 50-day simple moving average is $45.01 and its 200 day simple moving average is $47.68. The firm has a market cap of $2.56 billion, a P/E ratio of -8.31 and a beta of 0.34. Biohaven Pharmaceutical has a fifty-two week low of $29.17 and a fifty-two week high of $67.86.
In other Biohaven Pharmaceutical news, Director Eric Aguiar sold 10,000 shares of Biohaven Pharmaceutical stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $45.00, for a total transaction of $450,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Elyse Stock sold 800 shares of Biohaven Pharmaceutical stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $45.01, for a total value of $36,008.00. Following the transaction, the insider now owns 800 shares in the company, valued at $36,008. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,500 shares of company stock valued at $1,283,747. 23.90% of the stock is owned by insiders.
A number of hedge funds have recently bought and sold shares of BHVN. Marshall Wace LLP bought a new position in Biohaven Pharmaceutical during the first quarter worth about $365,000. Xact Kapitalforvaltning AB bought a new position in Biohaven Pharmaceutical during the second quarter worth about $320,000. Handelsbanken Fonder AB bought a new position in Biohaven Pharmaceutical during the second quarter worth about $6,656,000. Clear Street Markets LLC bought a new position in Biohaven Pharmaceutical during the second quarter worth about $335,000. Finally, Fox Run Management L.L.C. bought a new position in Biohaven Pharmaceutical during the second quarter worth about $434,000. Hedge funds and other institutional investors own 88.91% of the company’s stock.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Recommended Story: Earnings Reports
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.